You are in: eMedicine Specialties > Emergency Medicine > Rheumatology
|
Temporal Arteritis Last Updated: November 8, 2005 |
|
| Synonyms and related keywords: giant cell arteritis,
cranial arteritis,
vasculitis,
temporal-located headaches,
ischemic optic neuritis,
headache,
cephalgia,
impaired vision,
vision loss,
jaw claudication,
sixth nerve palsy,
afferent pupillary defect, arteritic ischemic optic neuropathy, temporal arteritis
|
|   |
AUTHOR INFORMATION
| Section 1 of 10  |
|
| Author: Ann G Egland, MD, Consulting Staff, Department of Operational and Emergency Medicine, Walter Reed Army Medical Center Coauthor(s): Leslie W Jackson, MD, LTC, MC, Assistant Professor, Department of Medicine, Uniformed Services University of the Health Sciences; Assistant Chief, Rheumatology Service, Department of Medicine, Walter Reed Army Medical Center |
| Ann G Egland, MD, is a member of the following medical societies:
American College of Emergency Physicians,
American Medical Association,
Association of Military Surgeons of the US,
Medical Society of Virginia, and
Society for Academic Emergency Medicine |
| Editor(s): Richard S Krause, MD, Clinical Assistant Professor, Residency Program Director, Department of Emergency Medicine, State University of New York at Buffalo School of Medicine; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine;
Gino A Farina, MD, Program Director, Associate Professor of Clinical Emergency Medicine, Department of Emergency Medicine, Long Island Jewish Medical Center, Albert Einstein College of Medicine;
John Halamka, MD, Chief Information Officer, CareGroup Healthcare System, Assistant Professor of Medicine, Department of Emergency Medicine, Beth Israel Deaconess Medical Center; Assistant Professor of Medicine, Harvard Medical School;
and Charles V Pollack, Jr, MD, MA, FACEP, Chairman, Professor of Emergency Medicine, Department of Emergency Medicine, Pennsylvania Hospital, University of Pennsylvania |
Disclosure
|   |
INTRODUCTION
| Section 2 of 10  |
|
Background: Temporal arteritis originates from a generalized vasculopathy affecting medium and large arteries. New-onset headache in any patient older than 50 years prompts consideration of this diagnosis.
Early recognition and treatment remain critical to prevent monocular or binocular blindness, as first reported in the literature in 1938.
Pathophysiology: Confusion surrounds the terminology used to classify this vasculitis. Temporal arteritis is a commonly used term, as inflammation often strikes the temporal artery, causing temporal-located headaches. In addition, findings from biopsy of the superficial temporal artery assist in establishing the diagnosis.
Giant cell arteritis, an alternative name for this disorder, describes the pathologic appearance of affected vessels infiltrated by lymphocytes, plasma cells, and multinucleated giant cells. Patchy or segmental changes overcome medium and large arteries of the head and neck and may extend into the carotids and aorta.
A cell-mediated immune response (oligoclonal T-cell expansion in peripheral blood lymphocytes) directed toward antigens in or near elastic tissue component of the arterial wall may account for this disorder. Pathologic alterations encountered with temporal arteritis also occur in other conditions, most notably polymyalgia rheumatica (PMR). However, PMR coexists with other disorders, and random biopsies of temporal arteries reveal positive findings in only 20% of patients with PMR.
Cytokine patterns of vasculitic lesions may help distinguish temporal arteritis, PMR, and additional inflammatory conditions.
Visual impairment results from inflammation of branches of the ophthalmic artery, particularly the posterior ciliary artery, leading to ischemic optic neuritis. Additionally, the central retinal artery is affected, and almost one half of cases involve loss of eyesight. Frequency:
- In the US: Temporal arteritis occurs relatively frequently, particularly in patients older than 50 years, with the occurrence ranging from 10 in 100,000 to 50 in 100,000.
- Internationally: Incidence rates appear higher in northern climates.
Mortality/Morbidity:
- Long-term survival of patients with temporal arteritis is the same as for the general population.
- Visual loss is the most worrisome morbidity associated with temporal arteritis, affecting as many as 50% of patients who are untreated.
- As many as 75% of patients experiencing visual disturbance in 1 eye develop visual loss in the contralateral eye within 3 weeks.
Race: Temporal arteritis occurs more frequently in Caucasian patients of northern European descent, yet rarely in blacks and Asians.
Sex: Women develop temporal arteritis 4-6 times more frequently than men.
Age: Temporal arteritis rarely occurs in patients younger than 50 years, with the mean age of onset at 70 years. High incidence, approaching 1%, exists in all patients older than 80 years.
|   |
CLINICAL
| Section 3 of 10  |
|
History: - Headache, the most universal symptom, presents in more than 85% of patients with temporal arteritis. It tends to be new or change in character from a previous headache pattern, yet few features distinguish a headache caused by temporal arteritis from those arising from other etiologies.
- Cephalgia tends to be unilateral, classically concentrating in the temporal region, but may present in a diffuse or bilateral distribution.
- Onset is apt to be indolent. It is frequently worse at night, and the headache gradually worsens over several days.
- Underlying pain described as a burning or jabbing sensation may involve the surface of the scalp and face more than intracranial components.
- Simple acts such as combing hair or resting the head on a pillow exacerbate pain, with severity precluding the wearing of a hat or glasses.
- Vision loss may present as the first symptom, with approximately 50% of patients complaining of impaired vision.
- Onset may occur suddenly and painlessly.
- Loss may be transient (amaurosis fugax-type picture) or permanent. Initial ocular disturbances may fluctuate, but blindness eventually occurs in 20-50% of untreated patients.
- Bilateral visual loss befalls more than 50% of untreated patients; the second eye usually is affected within 2-3 weeks of the first.
- Jaw claudication is especially prominent when patient is chewing or talking and occurs in more than one half (approximately 65%) of patients with temporal arteritis.
- Constitutional symptoms include anorexia and weight loss, fever and sweats, and malaise, fatigue, and depression.
- Based on the 1990 American College of Rheumatology criteria for classification of giant cell arteritis, 3 of the following 5 items must be present:
- Development of symptoms in patients older than 50 years
- New onset of headache or localized head pain
- Temporal artery tenderness to palpation
- Decreased pulsations not related to arteriosclerosis of cervical arteries
- Westergren erythrocyte sedimentation rate (WESR) greater than 50 mm/h
Physical: Perform a general physical examination to exclude other possible serious causes of headache and visual disturbance. - A low-grade fever and mild meningeal signs may accompany temporal arteritis.
- Carefully examine the head and face.
- Palpation of affected artery may reveal exquisite tenderness, warmth, and pulselessness.
- Inflamed arteries may be dilated and thickened, allowing vessels to be rolled between the fingers and skull.
- Inspect for tender scalp nodules or necrotic spots that may appear over any part of the scalp.
- Check for cranial nerve palsies (especially sixth nerve palsy).
- General eye examination is as follows:
- Check visual acuity and visual fields; vision loss may be profound, and the patient may be limited to counting fingers or worse.
- Test for an afferent pupillary defect.
- Slit lamp examination helps exclude other potential problems.
- Funduscopic inspection is as follows:
- Optic disc may appear pale and edematous with temporal arteritis.
- Screen for scattered cotton-wool patches and small flame hemorrhages.
- Look for distended, beaded retinal veins with temporal arteritis.
Causes: Temporal arteritis may be part of an immune-mediated process, although the cyclical nature of outbreaks in a study in Minnesota suggests a possible infectious etiology.
|   |
DIFFERENTIALS
| Section 4 of 10  |
|
Glaucoma, Acute Angle-Closure Headache, Migraine Iritis and Uveitis Orbital Infections Polymyalgia Rheumatica Retinal Artery Occlusion Retinal Vein Occlusion Stroke, Ischemic Temporal Arteritis
Transient Ischemic Attack Ultraviolet Keratitis
Other Problems to be Considered:
Amyloidosis |
|
Patient Education
|
|
Click here for patient education.
|
|
|
|
|
|   |
WORKUP
| Section 5 of 10  |
|
Lab Studies:
- Complete blood count - May reveal leukocytosis, mild anemia, or thrombocytosis
- Erythrocyte sedimentation rate
- Normal erythrocyte sedimentation rate (ESR) is approximately one half an individual's age (0.5 X age). For females, add 5 mm/h to the calculation ([0.5 X age] + 5).
- Most patients affected with temporal arteritis demonstrate an ESR greater than 80 mm/h.
- Approximately 10% of patients may have an ESR less than 30 mm/h.
- ESR serves as a useful guide to disease activity.
- C-reactive protein (CRP) level may be elevated (>2.4).
- CRP level may even be elevated in some patients with a normal ESR.
- Almost one half of patients with temporal arteritis have abnormal results of liver function tests.
Imaging Studies:
- Chest radiograph may be a useful screening test for a thoracic aneurysm.
- Ocular pneumoplethysmography, which cannot be obtained in the ED, aids in making the diagnosis of temporal arteritis.
- Intravenous fluorescein angiography may also be used to check for delayed choroidal filling.
Procedures:
- Definitive diagnosis relies on a temporal artery biopsy.
- Biopsy does not need to be performed urgently. It can be performed on an outpatient basis but not in the ED.
- Since infection tends to be patchy or segmental, multiple biopsies may be required. Perform bilateral biopsies if initial biopsy findings prove negative and clinical suspicion remains high.
- Steroid therapy may affect results of biopsy, but inflammatory changes usually persist for 2-4 weeks after initiation of treatment.
|   |
TREATMENT
| Section 6 of 10  |
|
Prehospital Care: Patients generally do not present via emergency medical services. Emergency Department Care: - Crucial to optimal ED care of a patient with temporal arteritis is maintaining a high index of suspicion and a low threshold to treat.
- Treatment normally incorporates high-dose prednisone, although some experts advocate intravenous methylprednisolone when visual symptoms are present for less than 48 hours.
Consultations: - Consult an ophthalmologist for a complete ocular examination for the patient to rule out other causes of vision loss, such as retinal pathology. This is especially important when the etiology of the visual disturbance remains unclear. The ophthalmologist may arrange for an outpatient temporal artery biopsy to confirm the diagnosis.
- Rheumatology or internal medicine usually directs general care for systemic complaints, monitors patients for remissions, and manages complications associated with steroid therapy.
|   |
MEDICATION
| Section 7 of 10  |
|
Systemic steroids should be started. Oral steroids are effective. IV steroids may be administered if visual deficit is established or if patient requires admission for other reasons.
Drug Category: Glucocorticoids -- Have anti-inflammatory properties and cause profound and varied metabolic effects. In addition, these agents modify the body's immune response to diverse stimuli. Drug Name
| Prednisone (Deltasone, Sterapred, Orasone) -- DOC in treatment of temporal arteritis. Useful in treatment of inflammatory and allergic reactions by reversing increased capillary permeability and suppressing PMN activity.
In prolonged treatment, taper over 1-2 wk.| Adult Dose | 1-2 mg/kg/d PO divided bid/qid
Alternatively, administer a maximum of 80 mg/d PO qd or divided bid/qid| Pediatric Dose | 4-5 mg/m2/d
Alternatively, administer 1-2 mg/kg PO qd| Contraindications | Documented hypersensitivity; viral infection; peptic ulcer disease; hepatic dysfunction; connective tissue infections; fungal or tubercular skin infections; GI disease; use with caution in patients with diabetes |
|---|
| Interactions | Coadministration with estrogens may decrease prednisone clearance; concurrent use with digoxin may cause digitalis toxicity secondary to hypokalemia; phenobarbital, phenytoin, and rifampin may increase metabolism of glucocorticoids (consider increasing maintenance dose); monitor for hypokalemia with coadministration of diuretics |
|---|
| Pregnancy |
B - Usually safe but benefits must outweigh the risks.
|
|---|
| Precautions | Abrupt discontinuation of glucocorticoids may cause adrenal crisis; hyperglycemia, edema, osteonecrosis, myopathy, peptic ulcer disease, hypokalemia, osteoporosis, euphoria, psychosis, myasthenia gravis, growth suppression, and infections may occur with glucocorticoid use |
|---|
|
|---|
|
|---|
| Drug Name
| Methylprednisolone (Solu-Medrol, Medrol, Depo-Medrol) -- Decreases inflammation by suppressing migration of PMNs and reversing increased capillary permeability. |
|---|
| Adult Dose | 125-250 mg IV loading dose, followed by 0.5-1 mg/kg/dose q6h, not to exceed 3 d |
|---|
| Pediatric Dose | 2 mg/kg IV loading dose, followed by 0.5-1 mg/kg/dose q6h, not to exceed 3 d |
|---|
| Contraindications | Documented hypersensitivity; viral, fungal, or tubercular skin infections; use with care in patients with diabetes |
|---|
| Interactions | Coadministration with digoxin may increase digitalis toxicity secondary to hypokalemia; estrogens may increase levels of methylprednisolone; phenobarbital, phenytoin, and rifampin may decrease levels of methylprednisolone (adjust dose); monitor patients for hypokalemia when taking medication concurrently with diuretics |
|---|
| Pregnancy |
C - Safety for use during pregnancy has not been established.
|
|---|
| Precautions | Hyperglycemia, edema, osteonecrosis, peptic ulcer disease, hypokalemia, osteoporosis, euphoria, psychosis, growth suppression, myopathy, and infections are possible complications of glucocorticoid use |
|---|
Drug Category: Immunosuppressants -- Suppress key factors of the immune system involved in immune reactions.Drug Name
| Azathioprine (Imuran) -- Antagonizes purine metabolism and inhibits synthesis of DNA, RNA, and proteins. May decrease proliferation of immune cells, which results in lower autoimmune activity. |
|---|
| Adult Dose | 1 mg/kg/d PO for 6-8 wk; increase by 0.5 mg/kg q4wk until response or dose reaches 2.5 mg/kg/d |
|---|
| Pediatric Dose | Initial dose: 2-5 mg/kg/d PO/IV
Maintenance dose: 1-2 mg/kg/d PO/IV| Contraindications | Documented hypersensitivity; low levels of serum thiopurine methyl transferase (TPMT) |
|---|
| Interactions | Toxicity increases with allopurinol; concurrent use with ACE inhibitors may induce severe leukopenia; may increase levels of MTX metabolites and decrease effects of anticoagulants, neuromuscular blockers, and cyclosporine |
|---|
| Pregnancy |
D - Unsafe in pregnancy
|
|---|
| Precautions | Increases risk of neoplasia; caution with liver disease and renal impairment; hematologic toxicities may occur; check TPMT level prior to therapy and monitor liver, renal, and hematologic function; pancreatitis rarely associated |
|---|
|
|---|
Drug Name
| Methotrexate (Folex PFS, Rheumatrex) -- Unknown mechanism of action in treatment of inflammatory reactions; may affect immune function. Ameliorates symptoms of inflammation (eg, pain, swelling, stiffness).
Adjust dose gradually to attain satisfactory response.| Adult Dose | 0.3 mg/kg/wk PO/IM; not to exceed 20 mg |
|---|
| Pediatric Dose | Not established |
|---|
| Contraindications | Documented hypersensitivity; alcoholism; hepatic insufficiency; documented immunodeficiency syndromes; preexisting blood dyscrasias (eg, bone marrow hypoplasia, leukopenia, thrombocytopenia, significant anemia); renal insufficiency |
|---|
| Interactions | Oral aminoglycosides may decrease absorption and blood levels of concurrent oral MTX; charcoal lowers MTX levels; coadministration with etretinate may increase hepatotoxicity of MTX; folic acid or its derivatives contained in some vitamins may decrease response to MTX
Probenecid, NSAIDs, salicylates, procarbazine, and sulfonamides, including TMP-SMZ, can increase MTX plasma levels; may decrease phenytoin plasma levels; may increase plasma levels of thiopurines| Pregnancy |
D - Unsafe in pregnancy
|
|---|
| Precautions | Monitor CBCs monthly and monitor liver and renal function q1-3mo during therapy (monitor more frequently during initial dosing, dose adjustments, or when risk of elevated MTX levels, eg, dehydration); MTX has toxic effects on hematologic, renal, GI, pulmonary, and neurologic systems; discontinue if significant drop in blood counts occurs; fatal reactions reported when administered concurrently with NSAIDs |
|---|
|
|---|
|
|---|
|   |
FOLLOW-UP
| Section 8 of 10  |
|
Further Inpatient Care:
- Admission depends upon severity of symptoms and associated medical problems and on the patient's ability to provide self-care at home.
Further Outpatient Care:
- Most patients can be treated on an outpatient basis.
- Prescribe a sufficient quantity of steroids to ensure proper compliance.
- Arrange follow-up care in 48-72 hours.
- Symptoms should begin to resolve within 1-3 days.
- Duration of maintenance therapy may last for 1 year or more, depending upon the patient's response.
In/Out Patient Meds:
- Nonsteroidal anti-inflammatory drugs, if not contraindicated, provide supplemental pain relief but do not prevent progressive vasculitis that may lead to blindness.
- Methotrexate or azathioprine may act as steroid-sparing agents.
Transfer:
- Consider transfer only if visual disturbance is severe and cannot be adequately evaluated and managed at the current facility.
Complications:
- Loss of vision is the most feared complication of misdiagnosed or untreated temporal arteritis. Temporal arteritis impairs sight in the affected eye, and as many as three fourths of patients with unilateral blindness lose vision in the contralateral eye within 3 weeks.
- Risk of thoracic aneurysms is 17 times higher in patients with temporal arteritis than in age-matched controls.
- Patients with temporal arteritis have twice the risk of abdominal aneurysms as those in the control population.
- Uncommon complications include the following:
- Renal disease (albuminuria)
Prognosis:
- Generally, temporal arteritis appears as a self-limited condition lasting up to 2 years.
- Treatment with corticosteroids produces dramatic relief of symptoms, possibly improves vision in the affected eye, and tends to prevent blindness in the contralateral eye (<1% incidence in 5-y follow-up period).
Patient Education:
- Emphasize compliance with long-term treatment and follow-up care to prevent subsequent morbidity.
- Encourage immediate follow-up care to discuss future need for temporal biopsy.
- Explain that existing loss of visual perception may not be regained, despite therapy.
|   |
MISCELLANEOUS
| Section 9 of 10  |
|
Medical/Legal Pitfalls:
- Failure to consider diagnosis in older patients (especially older patients with an elevated ESR)
- Failure to consider alternative causes of systemic illness with an elevated ESR, such as myeloma or other cancers, bacterial endocarditis, and chronic infections (eg, tuberculosis, human immunodeficiency virus [HIV])
- Failure to promptly initiate corticosteroid therapy
- Failure to administer corticosteroids pending results of temporal artery biopsy
- Failure to arrange timely follow-up care
Special Concerns:
- Suspect temporal arteritis as a possible diagnosis in an older patient with a high ESR and/or a normal white blood cell count, even absent specific features, such as headache or jaw claudication.
|   |
BIBLIOGRAPHY
| Section 10 of 10 |
|
-
Chan CC, Paine M, O'day J: Predictors of recurrent ischemic optic neuropathy in giant cell arteritis. J Neuroophthalmol 2005 Mar; 25(1): 14-7[Medline].
-
Cid MC, Font C, Oristrell J, et al: Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 1998 Jan; 41(1): 26-32[Medline].
-
Edmeads J: Headaches in older people. How are they different in this age group? Postgrad Med 1997 May; 101(5): 91-4, 98-100[Medline].
-
Gabriel SE, Sunku J, Salvarani C, et al: Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 1997 Oct; 40(10): 1873-8[Medline].
-
Gonzalez-Gay MA: Genetic epidemiology. Giant cell arteritis and polymyalgia rheumatica. Arthritis Res 2001; 3(3): 154-7[Medline].
-
Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, et al: Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore) 2000 Sep; 79(5): 283-92[Medline].
-
Hayreh SS, Podhajsky PA, Raman R, Zimmerman B: Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol 1997 Mar; 123(3): 285-96[Medline].
-
Hunder GG: Giant cell arteritis and polymyalgia rheumatica. Med Clin North Am 1997 Jan; 81(1): 195-219[Medline].
-
Krishna R, Kosmorsky GS: Implications of thrombocytosis in giant cell arteritis. Am J Ophthalmol 1997 Jul; 124(1): 103[Medline].
-
Kunimoto DY, Kannitkar KD, Makar MS: Arteritic Ischemic Neuropathy. In: The Wills Eye Manual. 4th ed. 2004; 227-228.
-
Nixon PP, Payne M, Franklin CD: Giant cell arteritis--a case report. Br Dent J 1997 Oct 11; 183(7): 260-2[Medline].
-
Nordborg E, Nordborg C, Malmvall BE, et al: Giant cell arteritis. Rheum Dis Clin North Am 1995 Nov; 21(4): 1013-26[Medline].
-
Smetana GW, Shmerling RH: Does this patient have temporal arteritis?. JAMA 2002 Jan 2; 287(1): 92-101[Medline].
-
Weyand CM, Bartley GB: Giant cell arteritis: new concepts in pathogenesis and implications for management. Am J Ophthalmol 1997 Mar; 123(3): 392-5[Medline].
-
Weyand CM, Tetzlaff N, Bjornsson J, et al: Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum 1997 Jan; 40(1): 19-26[Medline].
-
Younger DS: Vasculitis of the nervous system. Curr Opin Neurol 2004 Jun; 17(3): 317-36[Medline].
Temporal Arteritis excerpt |